MHMarjolein A. J. Hiel

Marjolein A. J. Hiel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marjolein A. J. Hiel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient perspectives on treatment outcomes and priorities in autoimmune bullous diseases: an exploratory survey among Dutch patients

    by Marjolein A. J. Hiel, Eva W. H. Korte, Maria C. Bolling, Joost M. Meijer, Barbara Horváth

    Introduction Autoimmune bullous diseases (AIBDs), comprising pemphigoid and pemphigus diseases, have seen limited therapeutic advances beyond rituximab for pemphigus vulgaris. As novel therapies are evaluated in clinical trials, well-defined, uniform and relevant outcomes with patient involvement are essential. To date, however, patient-reported outcomes remain underrepresented, leaving uncertainty about whether trial results genuinely reflect patients’ expectations. This study examines perspectives of patients with AIBD on treatment outcomes and priorities to ensure that future research focuses on what matters most to them. Methods A cross-sectional study was conducted among Dutch patients with AIBD between October 2023 and January 2024, using a self-developed questionnaire with both closed- and open-ended questions to assess patient perspectives on treatment outcomes and priorities, key factors in choosing a treatment, and indicators of treatment success. Results Regarding skin and/or mucous membrane complaints, ‘the formation of new blisters and wounds’ emerged as the most important complaint a treatment should address for both pemphigoid (43%) and pemphigus (86%) patients. In open-ended questions, patients with pemphigoid most frequently prioritized ‘pruritus’ (44%), while patients with pemphigus emphasized ‘pain’ (39%). Most important concerns regarding physical and daily functioning were ‘vision problems’ (20%), ‘sleep disturbances’ (20%), and ‘self-care difficulties’ (23%) for patients with pemphigoid, whereas patients with pemphigus most commonly cited 'eating and/or swallowing difficulties' (57%) and 'daily activity limitations' (41%). Regarding emotional/psychological functioning, both subgroups prioritized ‘anxiety and/or worry’ as most important concern (pemphigoid: 28%, pemphigus: 43%). Side effects were identified as the most important factor in choosing a treatment (pemphigoid: 41%, pemphigus: 39%). The absence of one or more symptoms and clinical signs (i.e., ‘no blisters’) was mentioned as the most important indicator of treatment success (pemphigoid: 88%, pemphigus: 91%), although minimal clinical signs (i.e., ‘minimal blisters’) were also considered acceptable (pemphigoid: 25%, pemphigus: 13%). Conclusion Patients with pemphigoid and pemphigus exhibit some distinct treatment priorities, reflecting their distinct pathomechanisms. Nonetheless, both subgroups consistently prioritize not only the resolution of disease-specific clinical signs but also preservation of physical and psychological well-being, underscoring the need for more holistic and patient-centred outcome measurement to ensure the establishment of meaningful, AIBD subgroup specific treatment outcomes.

  • Open Access

    Clinical Phenotype Transition in Pemphigus May Suggest Undertreatment with Rituximab: Findings from a Retrospective Single-Centre Analysis of Relapsed Patients

    by Anne-Lise Strandmoe, Marjolein A.J. Hiel, Joost M. Meijer, Laura L. van Nijen-Vos, A. Miranda Nijenhuis, L. Joost van Pelt, Gonnie H.J. Meijer, Peter Heeringa, Gilles F.H. Diercks, Jeroen Bremer, et al.

    Introduction: Pemphigus is an autoimmune bullous disease caused by autoantibodies against desmoglein (DSG) 1 and/or 3 and comprises two main subtypes: pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV affects the skin and/or mucosa and includes two forms: mucocutaneous PV (mcPV; anti-DSG1 and anti-DSG3) and mucosal PV (mPV; anti-DSG3). PF, characterized by anti-DSG1 autoantibodies, is limited to the skin. Pemphigus is effectively treated with rituximab, a B-cell-depleting therapy. However, about half of patients relapse, with a subset exhibiting a shift in clinical subtype following relapse, known as clinical phenotype transition. This study aimed to investigate clinical phenotype transition in relapsed pemphigus patients following rituximab treatment. Methods: A single-centre, exploratory retrospective cohort study was conducted, reviewing the medical records of patients with pemphigus who received at least one treatment cycle of rituximab between December 2006 and December 2023. Clinical and immunological data were collected at several time points during the first cycle of rituximab treatment. Results: A total of 109 patients were included, of whom 44% (48/109) achieved sustained complete remission, while 56% (61/109) experienced relapse. Among the 61 patients who relapsed, 26% (16/61) experienced a clinical phenotype transition. All had an initial diagnosis of mcPV. Among these, 75% (12/16) transitioned from mcPV to mPV and 25% (4/16) from mcPV to PF. Clinical phenotype transitioned patients often remained seropositive for anti-DSG3 at clinical remission, a pattern not observed in patients who did not experience a clinical phenotype transition. Conclusions: Clinical phenotype transition was observed exclusively in mcPV patients, suggesting that such changes do not represent a true alteration in disease subtype but rather reflect persistent activity of the same pathogenic autoantibody due to suboptimal B-cell depletion, suggesting undertreatment with rituximab. These findings support the need to refine rituximab treatment regimens to achieve complete B-cell depletion, reduce relapse rates, and optimize long-term disease control in pemphigus.

  • Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?

    by Barbara Horváth, Marjolein A. J. Hiel, Anne-Lise Strandmoe, Joost M. Meijer

    Pemphigus is a group of rare autoimmune blistering disorders affecting the skin and mucosal surfaces, caused by pathogenic immunoglobulin G (IgG) autoantibodies targeting desmosomal cadherins, specifically desmoglein-1 and desmoglein-3, which are key components of desmosomes. There are two main forms of pemphigus: pemphigus vulgaris (PV) and pemphigus foliaceus (PF), with PV being the most common. Pemphigus can be life-threatening owing to the progressive loss of the epidermal and epithelial barrier function. However, the introduction of rituximab, an anti-CD20 monoclonal antibody, has significantly improved treatment outcomes in pemphigus. This review provides a comprehensive overview of the current treatment landscape for pemphigus, highlighting both established and emerging therapeutic approaches.

  • Open Access

    Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments

    by Marjolein A J Hiel, Billal Tedbirt, Eva W H Korte, Maria C Bolling, Joost M Meijer, Phyllis I Spuls, Sjoukje van der Werf, Marc Yale, Pascal Joly, Barbara Horváth

    Background: Bullous pemphigoid (BP) is the most common autoimmune bullous disease. It is characterized by the development of tense blisters and pruritus. BP is a chronic disease that requires long-term treatment often associated with serious side effects. Developments in understanding the disease have led to novel treatment approaches evaluated in clinical trials. However, the pooling of trial data remains challenging due to inconsistent outcome reporting. Objectives: To provide an overview of BP outcome measurement over the last two decades by mapping and listing all previously reported treatment outcomes and outcome measurement instruments (OMIs). Methods: A large scoping review was performed using scientific databases and trial registries (January 2002–August 2025). Study selection and data extraction were performed independently by a minimum of two reviewers. Eligible study designs were clinical trials, prospective cohort studies and systematic reviews. Retrospective studies were excluded. All identified outcomes and OMIs were mapped into overarching domains for insights into outcome measurement trends over time, including the uptake of consensus definitions. Results: Eighty studies were included, consisting of clinical trials (n = 27), prospective cohort studies (n = 27) and systematic reviews (n = 26). A total of 659 outcomes were extracted verbatim and classified into 46 outcome domains across 10 outcome domain areas. Clinical response, safety and immunological response comprised a major part of outcome measurement. Moreover, steroid toxicity has increasingly been considered in clinical trials. Definitions and timepoints of clinical response varied considerably. An imbalance between patient-reported (PROs) and clinician-reported outcomes was revealed, with PROs being in the minority, as well as a diverging focus between primary analyses in clinical trials and secondary analyses in systematic reviews. OMIs used to measure patient impact and quality of life were mainly generic and only sparsely used. Conclusions: Over the past two decades, there has been considerable heterogeneity in reported outcomes and OMIs in BP research. Despite standardization efforts, most studies lack well-defined, consistent outcomes. Redefinition of some endpoints and a consensus-based approach towards outcome uniformity should bridge regulatory requirements with validated sensitive measurement and PROs. This approach would enhance the clinical relevance of trial endpoints while maintaining standardization, ultimately advancing research quality and therapeutic development.


  • Open Access

    Rituximab resistant pemphigus vulgaris successfully treated with obinutuzumab

    by Marjolein A.J. Hiel, Gilles F.H. Diercks, Maria C. Bolling, Jeroen Bremer, Joost M. Meijer, Barbara Horváth


  • Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review

    by Billal Tedbirt, Eva W. H. Korte, Marjolein A. J. Hiel, Joost M. Meijer, Maria C. Bolling, Phyllis I. Spuls, Sjoukje van der Werf, Marc Yale, Barbara Horváth, Pascal Joly

    Background Mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease that predominantly affects mucosae. Treatments for MMP often lack robust evidence and may be poorly tolerated, especially in elderly patients. Objective This scoping review aims to provide an overview of MMP outcome measurement of the last two decades by mapping and listing all previously reported outcomes and outcome measurement instruments (OMIs). Design A large scoping review was performed in scientific databases and trial registries (MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Web of Science, the International Clinical Trials Registry Platform and Clinicaltrials.gov) covering January 2002 to December 2023. Clinical trials, prospective cohort studies, and systematic reviews were included, while retrospective studies were excluded. Results Thirty-nine studies met the inclusion criteria, including 20 prospective cohort studies, 13 systematic reviews, and 6 clinical trials. A total of 285 outcomes were extracted verbatim and categorized into 29 domains and 9 overarching areas. The most commonly reported outcome areas were related to clinical response, safety, and resource use. The majority were investigator-reported outcomes (85%), with only 8% being patient-reported. Various OMIs (n = 14) were employed, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI) score and tools for assessing ocular impairment and quality of life. Reported outcomes and OMIs are very diverse due to the heterogeneity in the presentation of MMP. Conclusions The standardized use of consensus-based outcome definitions and high-quality instruments that consider the patient perspective is expected to increase the efficacy of future MMP research and can be achieved by consensus-based selection of outcomes and critical appraisal of the measurement properties of OMIs.


  • Open Access

    Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey

    by Eva W H Korte, Marjolein A J Hiel, Maria C Bolling, Patrick Dunn, Dédée F Murrell, Victoria P Werth, Marc Yale, Phyllis I Spuls, Joost M Meijer, Barbara Horváth

    This study analysed 32 failed drug development trials and surveyed 56 experts in the field of autoimmune bullous diseases to identify key challenges in bullous pemphigoid and pemphigus research. Clinical trials primarily failed due to unmet efficacy endpoints and recruitment difficulties, with experts highlighting the need to improve endpoint selection and patient enrolment strategies through international collaboration to develop more effective trial designs and advance new therapeutic options.

  • Bullous and Nonbullous Pemphigoid Associated With Prurigo Nodularis: Successful Treatment With Dupilumab

    by Marjolein A. J. Hiel, Laurens W. Barkema, Gilles F. H. Diercks, Maria C. Bolling, Jeroen Bremer, Barbara Horváth, Marie‐Louise A. Schuttelaar, Joost M. Meijer


  • Open Access

    Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions

    by Marjolein A J Hiel, Eva W H Korte, Billal Tedbirt, Marieke C Bolling, Joost M Meijer, Phyllis I Spuls, Sjoukje van der Werf, Marc Yale, Barbara Horváth, Pascal Joly

    Background: Pemphigus is an autoimmune bullous disease (AIBD) and has two main subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). For adequate interpretation and comparison of clinical studies in pemphigus, it is essential to have outcomes and outcome measurement instruments (OMIs) that are well-defined, uniform and relevant. Objectives: To provide a comprehensive overview of previously reported outcomes and OMIs in pemphigus clinical research over the past two decades. Methods: A systematic literature search was performed in the databases MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Web of Science and trial registries covering the period between January 2002 and December 2023. Clinical trials, prospective cohort studies and systematic reviews were included. Retrospective studies were excluded. All identified outcomes and their respective OMIs were grouped into outcome domains and areas. Results: From all the included studies (n = 205), a total of 1502 outcomes were extracted verbatim, categorized in 55 outcome domains and 11 outcome areas. We found a gradual increase in the number of published trials over the past two decades. The included studies mainly focused on ‘clinical response’ (92%), ‘safety monitoring’ (75%) and ‘immune response’ (61%). ‘Quality of life’ was sparsely reported (12%). Heterogeneity of reported outcomes was observed across all study designs. Within the outcome area ‘clinical response’, the proportion of defined outcomes based on the 2008 consensus statement has not been consistent over time. However, four recent clinical trials used primary endpoints based on the 2008 consensus definitions. Moreover, a broad spectrum of outcome measurement instruments (n = 65) was reported. Conclusions: This review showed a wide variety in reported outcomes and OMIs in pemphigus clinical research over the past two decades. Despite standardization efforts, most studies still lack well-defined, consistent and relevant outcomes and OMIs. However, a positive trend is emerging as four recent trials did use consensus-based definitions and patient-focused OMIs. Nevertheless, the outcomes are overly stringent, lack patient-centeredness, and do not include intermediate endpoints. Therefore, refinement of the 2008 expert consensus statement through collaborative efforts of all stakeholders is essential to promote uniformity in future pemphigus outcome measurement and to advance pemphigus drug development.